Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Chimeric Conjugates for Alzheimer’s Disease

In: Alzheimer’s Disease: Drug Discovery [Internet]. Brisbane (AU): Exon Publications; 2020 Dec 18. Chapter 10.
Affiliations
Free Books & Documents
Review

Chimeric Conjugates for Alzheimer’s Disease

Illham Dhala et al.
Free Books & Documents

Excerpt

Alzheimer’s disease is a complex, progressive, neurodegenerative disorder with a multifactorial etiology. More than one mechanism appears to be involved in its pathogenesis. Current treatment targeting only a single mechanism provides only symptomatic relief and is unable to stop the progression of the disease. There is a substantial unmet medical need to develop more efficacious drugs that can address all the causative factors that lead to the development and progression of Alzheimer’s disease. One of the strategies which has emerged is the development of chimeric conjugate compounds, in which multiple bioactive components are combined to form novel molecular entities, that can simultaneously regulate multiple mechanisms effectively. This chapter presents an overview of the various factors contributing to the pathophysiology of Alzheimer’s disease. Chimeric strategies that are being developed to supplement the single-mechanism targeting acetylcholinesterase drugs, which are currently available for the treatment of Alzheimer’s disease, are also exemplified.

PubMed Disclaimer

References

    1. Tobore Onojighofia Tobore On the etiopathogenesis and pathophysiology of Alzheimer’s disease: A comprehensive theoretical review. J Alzheimers Dis. 2019;68(2):417–37. doi: 10.3233/JAD-181052. - DOI - PubMed
    1. Qiu C, Kivipelto M, Von Strauss E. Epidemiology of Alzheimer’s disease: Occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11(2):111–28. - PMC - PubMed
    1. Sharma P, Srivastava P, Seth A, Tripathi PN, Banerjee AG. Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies. Prog Neurobiol. 2019;174(December 2018):53–89. doi: 10.1016/j.pneurobio.2018.12.006. - DOI - PubMed
    1. Silvestrelli G, Lanari A, Parnetti L. Treatment of Alzheimer’s disease: From pharmacology to a better understanding of disease pathophysiology. Mech Ageing Dev. 2006;127:148–57. doi: 10.1016/j.mad.2005.09.018. - DOI - PubMed
    1. Anand R, Gill KD, Mahdi AA. Neuropharmacology therapeutics of Alzheimer’s disease: Past, present and future. Neuropharmacology. 2014;76(Pt A):27–50. doi: 10.1016/j.neuropharm.2013.07.004. - DOI - PubMed

LinkOut - more resources